Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis

Launched by BEIJING TONGREN HOSPITAL · Mar 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a new medication called CM310 for patients who suffer from uncontrolled seasonal allergic rhinitis, commonly known as hay fever. This condition causes uncomfortable symptoms like sneezing, runny nose, and itchy eyes, especially during certain seasons when allergens like pollen are present. The goal of the study is to see if CM310 can help reduce these symptoms and improve the quality of life for people affected by this condition.

To participate in the trial, individuals must be aged 18 and older and willing to sign a consent form that explains the study. It's important to note that some people may not be eligible if they have certain medical conditions that could interfere with their participation. While the study is not yet recruiting participants, those who join can expect to receive the new treatment and be monitored closely by healthcare professionals to track its effects. This trial represents an opportunity to potentially help improve treatments for seasonal allergies.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Voluntarily sign the informed consent form.
• Exclusion Criteria:
• • Have any condition that are not suitable for participating in this study.